113 related articles for article (PubMed ID: 12061321)
1. Development and rapid dissemination of Merkel-cell carcinomatosis following therapy with fludarabine and rituximab for relapsing follicular lymphoma.
Cohen Y; Amir G; Polliack A
Eur J Haematol; 2002 Feb; 68(2):117-9. PubMed ID: 12061321
[TBL] [Abstract][Full Text] [Related]
2. Large-cell transformation of chronic lymphocytic leukemia and follicular lymphoma during or soon after treatment with fludarabine-rituximab-containing regimens: natural history- or therapy-related complication?
Cohen Y; Da'as N; Libster D; Amir G; Berrebi A; Polliack A
Eur J Haematol; 2002 Feb; 68(2):80-3. PubMed ID: 12038452
[TBL] [Abstract][Full Text] [Related]
3. Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: experience on 142 patients.
Zinzani PL; Pellegrini C; Broccoli A; Casadei B; Argnani L; Pileri S
Am J Hematol; 2013 Nov; 88(11):E273-6. PubMed ID: 23843267
[TBL] [Abstract][Full Text] [Related]
4. Retreatment with rituximab alone induces sustained remission in a patient with follicular lymphoma with multiple extranodal sites of involvement, relapsing soon after primary treatment with fludarabine-rituximab.
Cohen Y; Libster D; Da'as N; Amir G; Polliack A
Hematol J; 2003; 4(2):151-3. PubMed ID: 12750735
[TBL] [Abstract][Full Text] [Related]
5. Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: toxicities overcome its high antilymphoma effect. Results from a Spanish Cooperative Trial (LNHF-03).
Tomás JF; Montalbán C; De Sevilla AF; Martínez-López J; Díaz N; Canales M; Martínez R; Sánchez-Godoy P; Caballero MD; Peñalver J; Prieto E; Salar A; Burgaleta C; Queizán JA; Bajo R; De Oña R; De La Serna J
Leuk Lymphoma; 2011 Mar; 52(3):409-16. PubMed ID: 21275633
[TBL] [Abstract][Full Text] [Related]
6. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma.
Czuczman MS; Koryzna A; Mohr A; Stewart C; Donohue K; Blumenson L; Bernstein ZP; McCarthy P; Alam A; Hernandez-Ilizaliturri F; Skipper M; Brown K; Chanan-Khan A; Klippenstein D; Loud P; Rock MK; Benyunes M; Grillo-Lopez A; Bernstein SH
J Clin Oncol; 2005 Feb; 23(4):694-704. PubMed ID: 15681517
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS).
Morschhauser F; Mounier N; Sebban C; Brice P; Solal-Celigny P; Tilly H; Feugier P; Fermé C; Copin MC; Lamy T
Cancer; 2010 Sep; 116(18):4299-308. PubMed ID: 20549824
[TBL] [Abstract][Full Text] [Related]
8. Fatal West Nile Virus infection after rituximab/fludarabine--induced remission for non-Hodgkin's lymphoma.
Mawhorter SD; Sierk A; Staugaitis SM; Avery RK; Sobecks R; Prayson RA; Procop GW; Yen-Lieberman B
Clin Lymphoma Myeloma; 2005 Nov; 6(3):248-50. PubMed ID: 16354331
[TBL] [Abstract][Full Text] [Related]
9. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma.
McLaughlin P; Hagemeister FB; Rodriguez MA; Sarris AH; Pate O; Younes A; Lee MS; Dang NH; Romaguera JE; Preti AH; McAda N; Cabanillas F
Semin Oncol; 2000 Dec; 27(6 Suppl 12):37-41. PubMed ID: 11225999
[TBL] [Abstract][Full Text] [Related]
10. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone.
Di Gaetano N; Xiao Y; Erba E; Bassan R; Rambaldi A; Golay J; Introna M
Br J Haematol; 2001 Sep; 114(4):800-9. PubMed ID: 11564066
[TBL] [Abstract][Full Text] [Related]
11. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
12. Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma.
Sacchi S; Pozzi S; Marcheselli R; Federico M; Tucci A; Merli F; Orsucci L; Liberati M; Vallisa D; Brugiatelli M;
Cancer; 2007 Jul; 110(1):121-8. PubMed ID: 17503433
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.
Karmali R; Kassar M; Venugopal P; Shammo JM; Fung HC; Bayer R; O'Brien T; Gregory SA
Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):467-74. PubMed ID: 21700527
[TBL] [Abstract][Full Text] [Related]
14. [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
Forstpointner R; Hänel A; Repp R; Hermann S; Metzner B; Pott C; Hartmann F; Rothmann F; Böck HP; Wandt H; Unterhalt M; Hiddemann W
Dtsch Med Wochenschr; 2002 Oct; 127(43):2253-8. PubMed ID: 12397539
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of lymphoma with fludarabine combined with rituximab after immune thrombocytopenia induced by fludarabine.
Tsutsumi Y; Kanamori H; Minami H; Musashi M; Fukushima A; Ehira N; Yamato H; Obara S; Ogura N; Tanaka J; Asaka M; Imamura M; Masauzi N
Ann Hematol; 2005 Apr; 84(4):269-71. PubMed ID: 15592832
[TBL] [Abstract][Full Text] [Related]
16. Rapid growth of Merkel cell carcinoma after treatment with rituximab.
Wirges ML; Saporito F; Smith J
J Drugs Dermatol; 2006 Feb; 5(2):180-1. PubMed ID: 16485888
[TBL] [Abstract][Full Text] [Related]
17. Early initial therapy of advanced follicular lymphoma: the need for vigilance.
Sweetenham JW; Freedman AS
Leuk Lymphoma; 2011 Mar; 52(3):355-7. PubMed ID: 21323517
[No Abstract] [Full Text] [Related]
18. Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National LymphoCare Study.
Martin P; Byrtek M; Dawson K; Ziemiecki R; Friedberg JW; Cerhan JR; Flowers CR; Link BK
Cancer; 2013 Dec; 119(23):4129-36. PubMed ID: 24006156
[TBL] [Abstract][Full Text] [Related]
19. Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma.
Luminari S; Marcheselli L; Sacchi S; Pozzi S; Bari A; Ilariucci F; Stelitano C; Angrilli F; Lazzaro A; Baldini L
Cancer; 2009 May; 115(9):1906-13. PubMed ID: 19248044
[TBL] [Abstract][Full Text] [Related]
20. Significant thrombocytopenia associated with the addition of rituximab to a combination of fludarabine and cyclophosphamide in the treatment of relapsed follicular lymphoma.
Leo E; Scheuer L; Schmidt-Wolf IG; Kerowgan M; Schmitt C; Leo A; Baumbach T; Kraemer A; Mey U; Benner A; Parwaresch R; Ho AD
Eur J Haematol; 2004 Oct; 73(4):251-7. PubMed ID: 15347311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
